STOCK TITAN

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated news page for Kura Oncology (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kura Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kura Oncology's position in the market.

Rhea-AI Summary
Kura Oncology's investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation by the FDA for treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The drug shows potential for substantial improvement over existing therapies, with a registration-directed trial on track for completion by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kura Oncology, Inc. announces participation in Stifel 2024 Targeted Oncology Forum with CEO Troy Wilson scheduled for a virtual fireside chat. The event will be on April 17, 2024, at 11:30 a.m. ET / 8:30 a.m. PT. A live audio webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
conferences
-
Rhea-AI Summary
Kura Oncology announces granting of inducement awards to new employees under the 2023 Inducement Option Plan, consisting of nonstatutory stock options to purchase 49,500 shares of common stock, with an exercise price of $21.82 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kura Oncology announces dosing of KO-2806 in combination with cabozantinib in ccRCC cohort of FIT-001 trial, marking a significant milestone in their FTI program. The company aims to address resistance mechanisms and enhance antitumor activity in various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
none
-
Rhea-AI Summary
Kura Oncology, Inc. granted inducement awards of nonstatutory stock options to two new employees, totaling 93,000 shares of common stock. The options have an exercise price of $21.59 per share and will vest over four years. This move aligns with the Company's commitment to precision medicines for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
Rhea-AI Summary
Kura Oncology reports positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, with effective mitigation of differentiation syndrome. Completion of enrollment in registration-directed trial of ziftomenib in NPM1-m AML expected by mid-2024. $570 million in pro forma cash provides runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
Rhea-AI Summary
Kura Oncology initiates Phase 1 trial KOMET-008 to evaluate ziftomenib in combination with gilteritinib, FLAG-IDA, or LDAC for NPM1-mutant or KMT2A-rearranged AML patients, aiming to provide a new treatment option with promising safety and efficacy profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
Rhea-AI Summary
Kura Oncology, Inc. (NASDAQ: KURA) announces CEO's participation in three investor conferences to discuss precision medicines for cancer treatment. Live webcasts and replays will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences
-
Rhea-AI Summary
Kura Oncology, Inc. (KURA) will report Q4 and full year 2023 financial results on Feb 27, 2024. The company aims to advance precision medicines for cancer treatment with a webcast and conference call scheduled for the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
conferences earnings
Rhea-AI Summary
Kura Oncology, Inc. (Nasdaq: KURA) granted inducement awards of nonstatutory stock options to three new employees. Each stock option has an exercise price of $21.02 per share and will vest over four years, subject to the employees' continued service relationship with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

KURA Stock Data

1.48B
48.24M
1.75%
105.55%
13.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About KURA

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.